GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine

More

  • COPENHAGEN, Aug 26- Novo Nordisk said on Wednesday it would begin a Phase III trial of its treatment for diabetes that could be taken orally rather than by injection after "encouraging" results in previous trials. The oral tablet is a part of Novo Nordisk's effort to make treatment less painful for diabetes patients and minimize the use of needles.

  • INDIANAPOLIS— Shares of Eli Lilly rose Wednesday in premarket trading a day after the drugmaker said a federal court upheld a patent protecting one of its top-selling drugs, the cancer treatment Alimta. The Indianapolis company said Tuesday after markets closed that the U.S. District Court for the Southern District of Indiana ruled in Lilly's favor...

  • DES MOINES, Iowa— To protect a flock of rare chickens from the possibility of getting the bird flu, Iowa State University said Monday it has canceled classes for about 500 students at its poultry teaching and research farm. The Department of Animal Science is minimizing traffic to the poultry farm on 11 acres 3 miles south of the main Iowa State campus in Ames amid...

  • Amgen files for approval of parathyroid disorder drug Tuesday, 25 Aug 2015 | 1:13 PM ET

    NEW YORK— Biotech drugmaker Amgen said Tuesday it filed for marketing approval of a drug designed to treat a symptom of chronic kidney disease. Amgen asked the Food and Drug Administration to approve its drug etelcalcetide as a treatment for secondary hyperparathyroidism, a condition that can cause fragile bones, pain, and organ damage. The Thousand Oaks,...

  • Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...

  • NEW YORK— Swiss drugmaker Novartis is buying a potential once-a-month multiple sclerosis drug from GlaxoSmithKline and could pay more than $1 billion in the latest deal between the two companies. Novartis currently sells the drug as a treatment for a type of leukemia, the result of a larger deal with GlaxoSmithKline. Novartis aims to start a late-stage...

  • LOS ANGELES— An anti-abortion group released a snippet of video on Friday showing a California company executive discussing fetal tissue for research after a judge ruled the group could show the footage even if it was illegally recorded. Los Angeles Superior Court Judge Joanne O'Donnell rejected efforts by StemExpress to block the videos, though she said...

  • Despite the excitement, the drug's two manufacturers— Eli Lilly and Co. of Indianapolis and German partner Boehringer Ingelheim GmbH— have announced only that a three-year study they conducted showed the drug delayed the time until patients died of cardiovascular disease or suffered a heart attack or stroke. That brief summary, known as the top-line result,...

  • Early-stage breast cancer may not require surgery Thursday, 20 Aug 2015 | 12:48 PM ET
    Therese Taylor, who had a mastectomy four years ago after a diagnosis of ductal carcinoma in situ, which she now believes it was unnecessary, at home in Mississauga, Ontario, Canada, Aug. 19, 2015.

    Patients with early-stage breast cancer may not require a lumpectomy or a mastectomy so early on, reports The New York Times.

  • Aug 20- A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday. Besides burnishing the image of the year-old drug, Jardiance, the results could raise the...

  • Aug 20- Canada's Valeant Pharmaceuticals International Inc said it would buy privately owned Sprout Pharmaceuticals, whose drug became the first approved treatment this week for low sexual desire in women, for about $1 billion plus milestone payments. Addyi was approved on Tuesday by the U.S. Food and Drug Administration for pre-menopausal women, after...

  • Aug 20- Canada's Valeant Pharmaceuticals International Inc is nearing a deal to pay $1 billion for Sprout Pharmaceuticals, the company that just won approval to sell the first drug that aims to boost a woman's libido, the Wall Street Journal reported. The U.S. Food and Drug Administration late on Tuesday approved Sprout's drug for pre-menopausal women.

  • Aug 19- Medical device maker Boston Scientific Inc said its stent to prevent the blocking of arteries in the legs was approved in the United States, four years after the device was recalled outside the country due to partial or no deployments. Boston Scientific also develops another medical device called Eluvia Stent that uses Innova's technology and is...

  • Aug 19- Medical device maker Boston Scientific Inc said the U.S. Food and Drug Administration approved its device to prevent the block of arteries in the legs which leads to peripheral artery disease.

  • LOS ANGELES— Shannen Doherty is battling breast cancer that worsened during a lapse in her health insurance caused by her former business managers, the actress claimed in a lawsuit filed Wednesday. Doherty is suffering from cancer and wishes her a full recovery, "the company's attorney, Randall J. Dean, wrote in a statement. Doherty's husband, photographer Kurt...

  • USDA seeking proposals for production of bird flu vaccine Wednesday, 19 Aug 2015 | 10:58 AM ET

    And while there's no certainty the virus will reappear during southern migration this fall, the USDA plans to increase surveillance to catch any recurrence early and have hundreds of additional workers ready to euthanize infected flocks quickly as a means of avoiding the farm-to-farm spread. T.J. Myers, associate deputy administrator for veterinary...

  • Female libido pill took long, winding route to market Tuesday, 18 Aug 2015 | 8:10 PM ET

    The FDA had never approved a drug for that condition or any other female sexual disorders. —June 2010: A panel of FDA advisers votes unanimously against the drug, saying its benefits are outweighed by its risks, including side effects like dizziness, fatigue and fainting. —March 2013: Sprout resubmits the drug to FDA with additional data showing its benefits using a...

  • FDA OKs first drug to boost sexual desire in women Tuesday, 18 Aug 2015 | 6:55 PM ET

    The drug, Addyi, is the first approved by the FDA to treat sexual desire disorders in men or women.

  • Ruth Blauer, executive director of the Maine Association of Substance Abuse Programs— which was recently notified that a more than $570,000 state contract that has been in place for 13 years will end on Dec. 31— said thousands of Maine residents will be affected if she can't find private donors or another way to keep the programs running. A spokesman for the...

  • WASHINGTON— Lyme disease conjures memories of checking for ticks at camp and fretting over bug bites after hikes in the woods. But far from a summertime nuisance, Lyme is a potentially debilitating disease- and the subject of a vigorous debate in modern medicine. Lyme disease is caused by a strain of bacteria carried by certain ticks, primarily found in Northeast...